Symbiotec Pharmalab Limited (BOM:544889)

India · Delayed Price · Currency is INR

1,138.05

+3.65 (0.32%)

At close: Sep 10, 2026

Market Cap	72.85B
Revenue (ttm)	8.69B +27.5%
Net Income	1.10B +41.7%
EPS	19.00 +34.0%
Shares Out	n/a
PE Ratio	66.30
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,118
Open	1,136.10
Previous Close	1,134.40
Day's Range	1,115.00 - 1,193.90
52-Week Range	933.80 - 1,193.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Symbiotec Pharmalab

Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and d... [Read more]

Industry Medicinal Chemicals and Botanical Products

Founded 1995

Employees 1,915

Stock Exchange Bombay Stock Exchange

Ticker Symbol 544889

Full Company Profile

Financial Performance

In fiscal year 2026, Symbiotec Pharmalab's revenue was 8.69 billion, an increase of 15.65% compared to the previous year's 7.52 billion. Earnings were 1.10 billion, an increase of 13.53%.

Financial Statements